Chemotherapy combined with bevacizumab for the treatment of advanced lung adenocarcinoma cancer harboring EGFR‐ANXA2, EGFR‐RAD51, ATR and BRCA2 mutations: A case report
Here, we report a case of a 36‐year‐old female patient with metastatic non‐small cell lung cancer (NSCLC) harboring EGFR‐ANXA2 and EGFR‐RAD51 double fusion mutations with BRCA2 (nonsense mutation of exon 11) and ATR mutations (Exon 44 variable shear mutation) identified by next generation sequencing...
Main Authors: | Rui Zhong, Hui Li, Yanling Liu, Shuang Zhang, Jingjing Liu, Zhicheng Huang, Ying Cheng |
---|---|
Format: | Article |
Language: | English |
Published: |
Wiley
2020-02-01
|
Series: | Thoracic Cancer |
Subjects: | |
Online Access: | https://doi.org/10.1111/1759-7714.13286 |
Similar Items
-
Addition of bevacizumab to EGFR tyrosine kinase inhibitors in advanced NSCLC: an updated systematic review and meta-analysis
by: Haosheng Zheng, et al.
Published: (2024-01-01) -
Adenocarcinoma Harboring EGFR-RAD51 Fusion Treated With Osimertinib: A Case Report
by: Sunny Y. Lai, MD, et al.
Published: (2024-04-01) -
Efficacy of osimertinib and the role of sequential liquid biopsy in patients diagnosed with NSCLC harboring EGFR and BRAF mutations at baseline: insights from two case reports
by: Loc Carlo Bao, et al.
Published: (2024-03-01) -
Non-Small Cell Lung Cancer Harboring Concurrent <i>EGFR</i> Genomic Alterations: A Systematic Review and Critical Appraisal of the Double Dilemma
by: Valerio Gristina, et al.
Published: (2021-06-01) -
Molecular Divergence upon <i>EGFR</i>-TKI Resistance Could Be Dependent on the Exon Location of the Original <i>EGFR</i>-Sensitizing Mutation
by: Roberto Serna-Blasco, et al.
Published: (2022-09-01)